Close

Maxim Group Starts Cellular Biomedicine Group (CBMG) at Buy

September 21, 2016 5:28 PM EDT Send to a Friend
Maxim Group initiates coverage on Cellular Biomedicine Group (NASDAQ: CBMG) with a Buy rating and a price target of $16.00.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login